Clinical Trial

Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess efficacy and safety in patients with myopic chorioretinal atrophy. The main question it aims to answer are: • Percentage of changes in the chorioretinal atrophic area Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy. Researchers will compare non-therapeutic eye to see if the changes is significant different.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-12-12; most recent amendment 2025-08-12.
Status change: Recruiting → Active, Not Recruiting 2025-08-12
Status change: Not Yet Recruiting → Recruiting 2023-01-11
Trial Details
NCT Number NCT05658237
Lead Sponsor PharmaBio Corporation
Conditions Myopic Chorioretinal Atrophy
Enrollment 10 participants
Start Date 2023-02-17
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-15